Ed Kaye, Stoke Therapeutics CEO
Stoke teases early efficacy data for possible PhIII dose in lead Dravet syndrome program
Late last year, Stoke Therapeutics put out early data for its lead program, noting a potential efficacy signal in a handful of Dravet syndrome patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
